Schlumberger NV vs Smith & Nephew plc — how do they compare? Schlumberger NV trades at $52.85 (market cap $79.67B), while Smith & Nephew plc trades at $29.82 (market cap $12.54B). The key difference: Schlumberger NV is far larger — about 6.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| SLB | SNN | |
|---|---|---|
Market Cap | $79.67B | $12.54B |
Sector | Energy | Health |
52-Week High | $58.01 | $38.70 |
52-Week Low | $31.72 | $28.73 |
Enterprise Value | $88.40B | $15.57B |
Dividend Yield | 2.2% | 2.65% |
Signals from Pluang's Aura AI — not financial advice
SLB trades at $52.96, down 0.45% on the day, with a bullish technical signal from moving averages and oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.55, and maintains a consensus analyst price target of $63.00. Revenue for 2025 was $35.71 billion, with a net income margin of 8.53%, though margins have softened from prior years. Recent news highlights growth in digital and offshore segments, offset by Middle East challenges.
The outlook for SLB is positive, driven by earnings beats and robust analyst support, but risks include regional volatility and margin pressure. Upside potential exists if digital and production gains accelerate, yet investors must weigh debt levels and geopolitical headwinds against the stock's current valuation near 52-week highs.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Trailing returns across standard periods
Latest headlines on both assets
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →